Shots:

• The US FDA has granted FT designation to NVX-CoV2373 which is currently in late-phase clinical development. Novavax expects to initiate pivotal P-III study in the US & Mexico by the end of Nov’2020
• The company’s ongoing P-lll trial in the UK to evaluate the efficacy- safety- and immunogenicity of NVX-CoV2373 is expected to be fully enrolled by the end of Nov. Depending on the overall COVID-19 attack rate- interim data in the UK trial is expected in Q1’21
• NVXCoV2373 is a stable- prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant

­ Ref: Novavax | Image: Newsroom Keck Medicine of USC